The rs12916‐T variant in HMGCR was weakly associated with a decreased risk of prostate cancer overall (OR: 0.97; 95% CI: 0.94, 1.00; P = 0.03; I2 = 0%) (Fig. 3). Here, HMGCR is linked to prostate cancer.